Table 1 Baseline patient characteristics.

From: Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study

 

Patients (N = 40)

Age

   Median (IQR) age at initial diagnosis, years [mean ± SD]

3.5 (2.4–5.4) [3.9 ± 2.3]

   Median (IQR) age at informed consent, years [mean ± SD]

6.0 (4–7.5) [6.4 ± 3.5]

Sex

   Male

28 (70)

   Female

12 (30)

Race, white

40 (100)

Disease status

   Relapsed

23 (57)

   Refractory

17 (43)

Relapses since initial diagnosis

   None

17 (43)

   1

19 (48)

   2

4 (10)

INSS stage at initial diagnosis

   1

2 (5)

   2

0

   3

2 (5)

   4

36 (90)

MYCN amplification

   No

32 (80)

   Yes

7 (18)

   Missing

1 (3)

Bone marrow involvement

14 (35)

Soft tissue involvement

17 (43)

  1. INSS International Neuroblastoma Staging System, IQR interquartile range, SD standard deviation.
  2. Data are n (%) unless stated otherwise.
Back to article page